Related Experiment Video

Updated: Apr 11, 2026

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production
08:32

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production

Published on: March 2, 2014

11.0K

The c-Jun N-terminal kinase inhibitor SP600125 inhibits human cytomegalovirus replication

Huiping Zhang1, Xiaofeng Niu2, Zhikang Qian3

  • 1Department of Neonatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Journal of Medical Virology
|June 11, 2015
PubMed

Insights

New JNK inhibitors show promise in combating human cytomegalovirus (HCMV) replication. These compounds target early viral gene expression, offering a potential new therapeutic strategy against HCMV infection.

Area of Science:

  • Virology
  • Molecular Biology
  • Drug Discovery

Background:

  • Human cytomegalovirus (HCMV) is a significant opportunistic pathogen causing severe disease in vulnerable populations.
  • Current preventative vaccines and antiviral treatments for HCMV are limited by efficacy, side effects, and drug resistance.

Purpose of the Study:

  • To identify novel small molecule inhibitors targeting HCMV replication.
  • To investigate the mechanism of action and therapeutic potential of identified inhibitors.

Main Methods:

  • Conducted a chemical screen to identify anti-HCMV compounds.
  • Utilized cell culture models (human fibroblasts, retinal pigment epithelial cells) with HCMV laboratory and clinical strains.
  • Employed RNA interference to assess the role of c-Jun N-terminal kinase (JNK).
  • Analyzed viral gene transcription and protein accumulation.

Main Results:

  • Identified three distinct JNK inhibitors (SP600125, CC-401, JNK inhibitor VIII) that effectively inhibit HCMV replication.
  • SP600125 demonstrated efficacy against both laboratory and clinical HCMV strains.
  • JNK knockdown mimicked the antiviral effects of the inhibitors, confirming JNK's role.
  • SP600125 inhibited early viral gene transcription (IE1/2) and subsequent viral gene expression, without affecting viral binding, entry, or DNA delivery.

Conclusions:

  • JNK inhibitors represent a potential new class of antiviral drugs against HCMV.
  • JNK is a viable therapeutic target for developing novel anti-HCMV therapies.
Keywords:
SP600125antiviralc-Jun N-terminal kinasecytomegalovirus

More Related Videos

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.4K
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

14.5K

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
34
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
42
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
69
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
66